University of Wisconsin, Madison
Participants with metastatic cancer who are taking anti-PD-1 or anti-PD-L1 therapy will be enrolled to assess the safety of and find the optimal dose for radioactive imaging agents and to explore whether these agents will make current drug therapies work better. Up to 60 participants will be enrolled and can expect to be on study for up to 9 months.
This is a safety study of 86Y-NM600 and 90Y-NM600 and a dose finding study for 90Y-NM600 in patients with metastatic cancers who are receiving an anti-PD-1 or anti-PD-L1 therapy, have persistent disease that is stable or potentially progressive, and will be continuing anti-PD-1 or anti-PD-L1 therapy for another imaging interval per the treating physician. The imaging agent 86Y-NM600 will be injected, and serial positron-emission tomography (PET)/computed tomography (CT) imaging will be performed to enable dosimetry calculations that will be used to determine eligibility for 90Y-NM600. Phase 1…
Inclusion Criteria: 1. Participant must be informed of the investigational nature of the study and must be able to sign a written informed consent. 2. Participants with histologically or cytologically confirmed squamous cell carcinoma thought to originate from the head and neck region (HNC). 3. Participants must have metastatic solid malignancy, non-hematological. 4. Participants must be under treatment with one of the following FDA-approved standard-of-care anti-PD-1 or anti-PD-L1 therapies: Pembrolizumab (Keytruda; anti-PD-1 antibody), Nivolumab (Opdivo; anti-PD-1 antibody), Atezolizumab (T…
NM600 is a tumor-selective, pan-cancer, targeted radionuclide therapy (TRT) with theranostic capacity
Arctuva estimate
Verify or correct the compensation shown for this listing.